GeneDx (WGS) Competitors $101.04 +4.41 (+4.56%) As of 04/14/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock WGS vs. HIMS, OPCH, GH, RDNT, BTSG, SHC, SGRY, PRVA, CON, and LFSTShould you be buying GeneDx stock or one of its competitors? The main competitors of GeneDx include Hims & Hers Health (HIMS), Option Care Health (OPCH), Guardant Health (GH), RadNet (RDNT), BrightSpring Health Services (BTSG), Sotera Health (SHC), Surgery Partners (SGRY), Privia Health Group (PRVA), Concentra Group Holdings Parent (CON), and LifeStance Health Group (LFST). These companies are all part of the "healthcare" industry. GeneDx vs. Hims & Hers Health Option Care Health Guardant Health RadNet BrightSpring Health Services Sotera Health Surgery Partners Privia Health Group Concentra Group Holdings Parent LifeStance Health Group GeneDx (NASDAQ:WGS) and Hims & Hers Health (NYSE:HIMS) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, media sentiment, valuation, community ranking and institutional ownership. Do institutionals & insiders hold more shares of WGS or HIMS? 61.7% of GeneDx shares are owned by institutional investors. Comparatively, 63.5% of Hims & Hers Health shares are owned by institutional investors. 27.3% of GeneDx shares are owned by insiders. Comparatively, 17.7% of Hims & Hers Health shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has more risk and volatility, WGS or HIMS? GeneDx has a beta of 1.93, indicating that its share price is 93% more volatile than the S&P 500. Comparatively, Hims & Hers Health has a beta of 1.65, indicating that its share price is 65% more volatile than the S&P 500. Which has preferable earnings and valuation, WGS or HIMS? Hims & Hers Health has higher revenue and earnings than GeneDx. GeneDx is trading at a lower price-to-earnings ratio than Hims & Hers Health, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGeneDx$305.45M9.28-$175.77M-$1.96-51.55Hims & Hers Health$1.48B4.24-$23.55M$0.5452.24 Does the media favor WGS or HIMS? In the previous week, Hims & Hers Health had 10 more articles in the media than GeneDx. MarketBeat recorded 28 mentions for Hims & Hers Health and 18 mentions for GeneDx. GeneDx's average media sentiment score of 1.07 beat Hims & Hers Health's score of 0.77 indicating that GeneDx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GeneDx 12 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Hims & Hers Health 14 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community prefer WGS or HIMS? Hims & Hers Health received 32 more outperform votes than GeneDx when rated by MarketBeat users. However, 47.83% of users gave GeneDx an outperform vote while only 36.44% of users gave Hims & Hers Health an outperform vote. CompanyUnderperformOutperformGeneDxOutperform Votes1147.83% Underperform Votes1252.17% Hims & Hers HealthOutperform Votes4336.44% Underperform Votes7563.56% Is WGS or HIMS more profitable? Hims & Hers Health has a net margin of 8.19% compared to GeneDx's net margin of -17.12%. Hims & Hers Health's return on equity of 10.97% beat GeneDx's return on equity.Company Net Margins Return on Equity Return on Assets GeneDx-17.12% 3.33% 1.69% Hims & Hers Health 8.19%10.97%8.29% Do analysts prefer WGS or HIMS? GeneDx presently has a consensus target price of $72.33, suggesting a potential downside of 28.41%. Hims & Hers Health has a consensus target price of $38.25, suggesting a potential upside of 35.59%. Given Hims & Hers Health's higher possible upside, analysts clearly believe Hims & Hers Health is more favorable than GeneDx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GeneDx 0 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50Hims & Hers Health 2 Sell rating(s) 7 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.21 SummaryHims & Hers Health beats GeneDx on 12 of the 18 factors compared between the two stocks. Remove Ads Get GeneDx News Delivered to You Automatically Sign up to receive the latest news and ratings for WGS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart WGS vs. The Competition Export to ExcelMetricGeneDxHealth services IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.84B$1.04B$5.35B$7.58BDividend YieldN/A2.62%5.11%4.33%P/E Ratio-51.5551.1121.6817.78Price / Sales9.283.71376.3394.47Price / CashN/A26.1438.1534.64Price / Book11.514.236.443.99Net Income-$175.77M-$5.50M$3.20B$247.24M7 Day Performance17.54%310.99%9.01%8.29%1 Month Performance2.61%295.65%-6.09%-5.37%1 Year Performance922.67%202.85%10.72%-0.24% GeneDx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)WGSGeneDx1.8064 of 5 stars$101.04+4.6%$72.33-28.4%+950.3%$2.84B$305.45M-51.551,200Positive NewsGap DownHIMSHims & Hers Health3.5748 of 5 stars$27.71+6.6%$37.31+34.7%+102.1%$6.16B$1.48B62.97650Gap UpOPCHOption Care Health3.1288 of 5 stars$32.87-2.0%$33.00+0.4%+4.7%$5.40B$5.00B27.625,600Short Interest ↑Positive NewsGHGuardant Health3.6834 of 5 stars$41.78+3.0%$48.95+17.2%+147.3%$5.16B$739.02M-11.741,790Gap UpRDNTRadNet3.8273 of 5 stars$49.29+1.2%$73.25+48.6%+10.0%$3.65B$1.83B-704.048,970News CoveragePositive NewsGap UpHigh Trading VolumeBTSGBrightSpring Health Services2.8945 of 5 stars$17.28+0.8%$21.67+25.4%+70.1%$3.02B$11.27B-66.4635,000Gap DownSHCSotera Health2.3755 of 5 stars$10.23-1.1%$16.00+56.4%-5.9%$2.90B$1.10B40.923,000Gap DownSGRYSurgery Partners2.8591 of 5 stars$20.51-2.8%$36.63+78.6%-19.0%$2.62B$3.11B-42.7313,500Positive NewsGap DownPRVAPrivia Health Group3.7775 of 5 stars$21.48-2.2%$26.67+24.1%+29.7%$2.59B$1.74B214.82810High Trading VolumeCONConcentra Group Holdings ParentN/A$20.19-2.1%$28.50+41.2%N/A$2.57B$1.90B13.3711,000Positive NewsGap DownLFSTLifeStance Health Group1.8866 of 5 stars$6.51-2.0%$8.50+30.6%+13.2%$2.50B$1.25B-25.046,640 Remove Ads Related Companies and Tools Related Companies HIMS Competitors OPCH Competitors GH Competitors RDNT Competitors BTSG Competitors SHC Competitors SGRY Competitors PRVA Competitors CON Competitors LFST Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:WGS) was last updated on 4/15/2025 by MarketBeat.com Staff From Our PartnersGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE tax surpriseElon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax auth...Altimetry | SponsoredAmazon ShockerJeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GeneDx Holdings Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share GeneDx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
